Extended Data Fig. 1: Trim28+/D9 male mice exhibit multi-cancer syndrome.

Shading represents data from endpoint tumors. a) Distribution of genotypes in the F1 male population. N = 172 male mice. b) Prevalence of malignant (black) or benign (white) endpoint tumors by genotype, as percentage of total endpoint tumors per genotype. N=37 malignant and benign endpoint tumors in male mice (8 in WT, 12 in Trim28+/D9, 7 in Tp53R270H/+, 10 in Tp53R270H/+;Trim28+/D9). c) Tissues targeted by malignant endpoint tumors. Top: mouse anatomy plots; non-targeted tissues in light-grey and targeted tissues colored by genotype: WT (black), Trim28+/D9 (orange), Tp53R270H/+ (green), Tp53R270H/+;Trim28+/D9 (purple). Bottom: percentage of male mice with specific organs targeted by malignant endpoint tumors in the different genotypes, as percentage of total animals with malignant endpoint tumors. N=19 mice with malignant endpoint tumors (4 WT, 7 Trim28+/D9, 3 Tp53R270H/+, 5 Tp53R270H/+;Trim28+/D9). d) Prevalence of malignant endpoint tumor types by genotype, as percentage of malignant endpoint tumors in each genotype. N=27 total malignant endpoint tumors in male mice (5 in WT, 10 in Trim28+/D9, 6 in Tp53R270H/+, 6 in Tp53R270H/+;Trim28+/D9). e) Fraction of animals with 0 or multiple malignant endpoint tumors by genotype, as percentage of male mice screened at the endpoint. N=21 endpoint mice (5 WT, 6 Trim28+/D9, 4 Tp53R270H/+, 5 Tp53R270H/+;Trim28+/D9). f) Prevalence of malignant tumor types by genotype, divided into aggressive (left) and endpoint (right), as percentage of total number male mice with aggressive or endpoint tumors, respectively. N=36 male mice with aggressive tumors (1 WT, 7 Trim28+/D9, 12 Tp53R270H/+, 16 Tp53R270H/+;Trim28+/D9), N=19 with endpoint tumors (4 WT, 7 Trim28+/D9, 3 Tp53R270H/+, 5 Tp53R270H/+;Trim28+/D9). Tumor categories are color-coded on the right: age-related carcinoma (red); carcinoma (gold); leukemia (light-green); lymphoma (light-blue); sarcoma (pink); germ-cell tumors (dark-green). Panel c, top created with BioRender.com.